AR020093A1 - Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico - Google Patents
Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleicoInfo
- Publication number
- AR020093A1 AR020093A1 ARP990102962A ARP990102962A AR020093A1 AR 020093 A1 AR020093 A1 AR 020093A1 AR P990102962 A ARP990102962 A AR P990102962A AR P990102962 A ARP990102962 A AR P990102962A AR 020093 A1 AR020093 A1 AR 020093A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- virus
- strain
- nucleic acid
- isolated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una cepa aislada del virus de hepatitis, un ácido nucleico aislado que codifica un polipéptido de la cepa aislada de virus, un vector que comprende dichoácido nucleico, un sistema vector huésped para la produccion de polipéptido de la cepa aislada devirus, un método para producir dicho polipéptido, un métodopara producir un péptido, un polipéptido de dicha cepa aislada de virus, un oligonucleotido para hibridarse dentro del ácido nucleico, método para obtneranticuerpos paa el polipéptido, un anticuerpo obtenido por el método, un método paa determinar la infeccion en un sujeto, un método para identificar uncompuesto químico, una composicion que comprende un péptido, un método para tratar un sujeto infectado, un método para evitar una infeccion, un método pararastrear fluidos en el sujeto, una vacuna contra hepatitis que comprende la cepa del virus de hepatitis. Esta invencion provee una cepa aislada de virus dehepatitis B designada antígeno de superficie de virus de hepatitis B humana-cepaS133 Oon (metionina a trionina) cuyo genoma viral constituyente estádepositado bajo los numeros de acceso P97121501, P97121502 y P97212503 en la Coleccion Europea de Cultivos de Células el 15 de diciembre de 1997. Estainvencion provee también unácido nucleico aislado que codifica un polipéptido que es un antígeno mayor mutante de superficie de una cepa de virus de hepatitisB. La aislacion del virus mutante permite el secuenciado de los ácidos nucleicos y los polipéptidos de los virus los cuales a cambio permiten la produccion devarios métodos los cuales no son posibles previo a la aislacion del virus. Estos métodos incluyen, pero no son limitantes a los métodos de deteccion deinfeccion, métodos de tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG1998/000046 WO1999066048A1 (en) | 1998-06-19 | 1998-06-19 | A mutant human hepatitis b viral strain and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020093A1 true AR020093A1 (es) | 2002-04-10 |
Family
ID=20429862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102962A AR020093A1 (es) | 1998-06-19 | 1999-06-18 | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6558675B1 (es) |
| EP (1) | EP1098981A1 (es) |
| JP (1) | JP2002518014A (es) |
| KR (1) | KR100498118B1 (es) |
| CN (1) | CN1322251A (es) |
| AR (1) | AR020093A1 (es) |
| AU (1) | AU756866B2 (es) |
| BG (1) | BG105066A (es) |
| BR (1) | BR9815913A (es) |
| CA (1) | CA2330935C (es) |
| HU (1) | HUP0103409A3 (es) |
| IL (1) | IL140364A0 (es) |
| IS (1) | IS5778A (es) |
| MX (1) | MXPA00012720A (es) |
| MY (1) | MY118955A (es) |
| NO (1) | NO20006456L (es) |
| NZ (1) | NZ508890A (es) |
| PL (1) | PL192129B1 (es) |
| TR (1) | TR200003777T2 (es) |
| UA (1) | UA73476C2 (es) |
| WO (1) | WO1999066048A1 (es) |
| YU (1) | YU80600A (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200643171A (en) | 2005-06-07 | 2006-12-16 | Temasek Life Sciences Lab Ltd | Porcine circovirus type 2 vaccines |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| WO1998011916A1 (en) | 1996-09-18 | 1998-03-26 | The Board Of Regents Of The University Of Texas System | Viral defective interfering particles and uses thereof |
-
1998
- 1998-06-19 UA UA2000127297A patent/UA73476C2/uk unknown
- 1998-06-19 US US09/719,528 patent/US6558675B1/en not_active Expired - Fee Related
- 1998-06-19 AU AU77951/98A patent/AU756866B2/en not_active Ceased
- 1998-06-19 EP EP98926023A patent/EP1098981A1/en not_active Withdrawn
- 1998-06-19 WO PCT/SG1998/000046 patent/WO1999066048A1/en not_active Application Discontinuation
- 1998-06-19 TR TR2000/03777T patent/TR200003777T2/xx unknown
- 1998-06-19 KR KR10-2000-7014456A patent/KR100498118B1/ko not_active IP Right Cessation
- 1998-06-19 NZ NZ508890A patent/NZ508890A/en unknown
- 1998-06-19 MX MXPA00012720A patent/MXPA00012720A/es not_active Application Discontinuation
- 1998-06-19 IL IL14036498A patent/IL140364A0/xx unknown
- 1998-06-19 HU HU0103409A patent/HUP0103409A3/hu unknown
- 1998-06-19 YU YU80600A patent/YU80600A/sh unknown
- 1998-06-19 CA CA002330935A patent/CA2330935C/en not_active Expired - Fee Related
- 1998-06-19 BR BR9815913-5A patent/BR9815913A/pt not_active Application Discontinuation
- 1998-06-19 JP JP2000554857A patent/JP2002518014A/ja active Pending
- 1998-06-19 PL PL345573A patent/PL192129B1/pl not_active IP Right Cessation
- 1998-06-19 CN CN98814201A patent/CN1322251A/zh active Pending
-
1999
- 1999-06-18 AR ARP990102962A patent/AR020093A1/es unknown
- 1999-06-18 MY MYPI99002517A patent/MY118955A/en unknown
-
2000
- 2000-12-18 NO NO20006456A patent/NO20006456L/no not_active Application Discontinuation
- 2000-12-18 BG BG105066A patent/BG105066A/xx unknown
- 2000-12-19 IS IS5778A patent/IS5778A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9815913A (pt) | 2001-12-26 |
| KR100498118B1 (ko) | 2005-07-01 |
| IL140364A0 (en) | 2002-02-10 |
| CN1322251A (zh) | 2001-11-14 |
| IS5778A (is) | 2000-12-19 |
| JP2002518014A (ja) | 2002-06-25 |
| CA2330935C (en) | 2005-05-10 |
| PL192129B1 (pl) | 2006-09-29 |
| WO1999066048A1 (en) | 1999-12-23 |
| KR20010106129A (ko) | 2001-11-29 |
| US6558675B1 (en) | 2003-05-06 |
| YU80600A (sh) | 2005-06-10 |
| HUP0103409A3 (en) | 2003-10-28 |
| EP1098981A1 (en) | 2001-05-16 |
| PL345573A1 (en) | 2001-12-17 |
| NZ508890A (en) | 2004-04-30 |
| NO20006456L (no) | 2001-02-16 |
| UA73476C2 (en) | 2005-08-15 |
| NO20006456D0 (no) | 2000-12-18 |
| AU7795198A (en) | 2000-01-05 |
| HUP0103409A2 (hu) | 2001-12-28 |
| MY118955A (en) | 2005-02-28 |
| CA2330935A1 (en) | 1999-12-23 |
| AU756866B2 (en) | 2003-01-23 |
| BG105066A (en) | 2001-09-28 |
| TR200003777T2 (tr) | 2001-06-21 |
| MXPA00012720A (es) | 2002-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111592602B (zh) | 一种β冠状病毒抗原、其制备方法和应用 | |
| Hanke et al. | Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice | |
| CA1265648A (en) | Leukemia-associated virus immunogen, vaccine and assay | |
| CN101918440B (zh) | 禽类细胞因子及编码其的遗传序列的应用 | |
| JPH06509710A (ja) | バキュロウイルスにおけるインフルエンザａのｍ２蛋白の改良発現及びｍ２蛋白の使用 | |
| Strand et al. | Structural proteins of mammalian oncogenic RNA viruses: immunological characterization of the p15 polypeptide of Rauscher murine virus | |
| Delbac et al. | On proteins of the microsporidian invasive apparatus: complete sequence of a polar tube protein of Encephalitozoon cuniculi | |
| AR020092A1 (es) | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptido | |
| CA2427578A1 (en) | A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine | |
| WO1989002277A2 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
| Camacho et al. | Protein p22 of African swine fever virus: an early structural protein that is incorporated into the membrane of infected cells | |
| Bai et al. | Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses | |
| Emini et al. | Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine | |
| CN101706497A (zh) | 人tff3的elisa检测试剂盒 | |
| RU2181379C2 (ru) | Пептид (варианты) и способ его производства, фармацевтическое средство, антитело и способ его производства | |
| AR020093A1 (es) | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico | |
| CA2338886A1 (en) | Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response | |
| WO2000004921A1 (en) | Avian leukosis virus subgroup j envelope gene product for diagnosis and vaccine | |
| Zhang et al. | Mapping of the epitopes of Epstein—Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants | |
| KR101526886B1 (ko) | 가금 아데노바이러스 섬유 2 단백질의 항원 결정기를 포함하는 재조합 단백질 및 이에 대한 항체 | |
| Al-Kubati et al. | Immunoinformatic prediction of the pathogenicity of bovine viral diarrhea virus genotypes: implications for viral virulence determinants, designing novel diagnostic assays and vaccines development | |
| KR100785397B1 (ko) | 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신 | |
| CA2491726A1 (en) | Feline infectious peritonitis vaccine | |
| AU643506B2 (en) | Polypeptides and DNA encoding same, associated with human malaria parasites | |
| CN115894713B (zh) | 异源三聚体化融合蛋白、组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |